NCT03770455View on ClinicalTrials.gov

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

December 17, 2020

Study Completion Date

January 7, 2021

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Avelumab

Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT

DRUG

2nd generation ADT (abiraterone or enzalutamide)

2nd generation ADT (abiraterone or enzalutamide)

Trial Locations (1)

70112

Tulane University School of Medicine, New Orleans

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

Jodi Layton, MD

OTHER

NCT03770455 - Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Biotech Hunter | Biotech Hunter